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Th   roughout medicine, investigators are in hot pursuit of 
biomarkers. Th  ese biomarkers, many of which involve 
multiplex assays or ‘omic’ technologies, come in a variety 
of ﬂ  avors: antecedent (disease risk); screening (subclinical 
disease); diagnostic; staging; and prognostic. Among 
their uses, biomarkers can help elucidate genetic 
predisposition to disease and identify triggering events; 
practically, such markers can allow early diagnosis and 
treatment and the development of strategies for risk 
reduction. Although biomarker technology can be 
unbelievably complex, the principles are straightforward 
and provide hope for improved patient outcomes.
As the study by Li and colleagues in Arthritis Research 
and Th  erapy indicates [1], the use of antinuclear anti-
bodies (ANAs), one of the most venerable tests in 
immuno  logy, as antecedent or screening biomarkers, 
while potentially very informative, faces major challenges. 
Amongst these, the frequency of serological positivity in 
the general population is probably the greatest. While the 
actual frequency of positive assays varies with method-
ology, nevertheless, up to 20% or more of otherwise 
healthy people can express an ANA [2]. Th   e expression of 
these antibodies does not appear related to age despite 
ideas that immunosenescence may promote autoreactivty 
[1].
Th  e basis of this seropositivity is puzzling. One 
possibility is that ANA reactivity represents vagaries of 
the assays, allowing detection of antibodies of either low 
titer or low avidity. Many nuclear antigens are highly 
charged molecules, with DNA and histones the prime 
examples. As such, ANA binding may occur by charge-
charge interactions or cross-reactivity with other 
antigens (also charged). In this regard, solid phase or 
multiplex assays may reveal a diﬀ  erent perspective on 
serology than the classic (and now antiquated) methods. 
Th   ese older assays required large amounts of antibody for 
detection, such as the formation of precipitating com-
plexes in immunodiﬀ  usion assays [3]. As a result, sero-
positivity indicated a robust response. While the solid 
phase and multiplex assays are sensitive and allow high 
throughput, their interpretation requires caution, espe-
cially in the setting of preclinical or subclinical disease, 
where the measured responses may be low [4,5].
Another explanation for the frequency of ANA expres-
sion in the general population relates to intrinsic 
immuno  logical disturbances among humans. Perhaps as 
a species, humans are predisposed to autoimmunity, with 
ANA expression the tip of the iceberg of autoimmunity. 
In animal models, ANA production can occur in the 
absence of other manifestations of systemic lupus erythe-
matosus, reﬂ   ecting the actions of speciﬁ   c genes that 
promote immune cell activity. While studies in mice 
involve intentional eﬀ   orts to isolate genes for auto-
immunity, the human genome may nevertheless contain 
numerous polymorphisms to increase species ﬁ  tness to 
ﬁ  ght  oﬀ    infection or heal wounds [6]. Indeed, the 
selective pressure created by infection can be profound, 
with the evolution of genes for nitric oxide production, 
for example, implicated in a predisposition to diseases 
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© 2011 BioMed Central Ltdsuch as lupus and rheumatoid arthritis as well as defense 
against malaria [7]. Certainly, more extensive analysis of 
the serology of various racial and ethnic groups would be 
informative, as would the study of populations in other 
locales [8].
As shown in this and other studies, ANA reactivity is 
greater in women than men, although these gender 
diﬀ  erences did not occur with antibodies to citrullinated 
proteins. In an era of genetics and personalized medicine, 
the biological diﬀ   erences between women and men 
sometimes do not get the attention they deserve. While 
the role of hormones compared to the genetic endow-
ment of two Xs versus an XY tandem can be debated, 
nevertheless, women appear predisposed to lupus as well 
as baseline ANA reactivity. In the future, consideration of 
the role of pregnancy in ANA reactivity seems worth-
while since, during normal pregnancy, there can be 
extensive exposure to nuclear antigens. Furthermore, 
although often considered a time of immunosuppression, 
pregnancy actually shows a surge of inﬂ  ammatory 
activity that could impact on immune responsiveness 
[9,10].
As almost every study has demonstrated, lupus is an 
enormously complex condition, with each patient dis-
play  ing a seemingly unique set of immunological distur-
bances and clinical and serological manifestations. In this 
circumstance, the chances of ﬁ  nding antecedent markers, 
including gene signatures, may be limited. Indeed, in the 
current study, the array studies produced surprising 
results since some healthy subjects without autoanti-
bodies had greater gene up-regulation than those with 
autoantibodies [1]. More work will be needed to under-
stand the interplay between gene expression and serology 
as well as the determinants of the interferon signature, 
which has been linked to immune complexes composed 
of ANAs.
In the real world of patient care, when confronting a 
positive ANA in a patient without clinical disease but 
consistent symptoms, the physician and patient want to 
know who will develop lupus and who will be spared, 
whether by luck, happenstance or even preventative 
measures such as very early therapy. Th  e road to that 
point will be long but the study by Li and colleagues is a 
very promising start of the journey.
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